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Abstract 
This report is in extension of that presented in International Journal of Sciences: Basic and Applied Research 
(IJSBAR) by the current researcher (author) in respect of “site attachment inhibition (or, negation of cellular 
attachment by viruses)” as a new pathway for development of antiviral drugs (therapies) given the lack of 
success by the two pathways established to date which have focused on "virus replication" and "immune system 
enhancement."  In that research report, the new antiviral treatment pathway was clearly delineated and 
supported in a number of ways including the example of HIV with CCR5-Δ32 mutation creating innate 
resistance (or, immunity) by way of subsequent site attachment inhibition, in addition to other blockade support. 
This report presents the conceptualization of “site attachment inhibition of bacteria (or, negation of cellular 
attachment by bacteria)” as a new pathway in antimicrobial treatment, in addition to consideration of other 
potential pathways. The pathway appears viable, although not appearing as robust at this stage as that for 
antiviral therapy.  The author of the current report has been invited to present the new strategic pathway 
delineated, specifically site attachment inhibition (or, negation of cellular attachment by infective agents), at the 
6th International Conference on Immunology (USA; Chicago IL 870th Congress) and related presentations of 
the official International Conference Series Umbrella including Rome, Italy.     
Keywords: Antimicrobial; Bacteria; CCR5-Δ32; Covalent Bonds; Electromagnetic Radiation; Glycoprotein; 
Microorganism; Resistance.    
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1. Introduction  
The concern with respect to antimicrobial resistance and the associated health threat has gained increasing 
attention.  There has been difficulty in gaining traction with respect to the issue and, given the lack of success, 
ongoing attention directed toward the issue is required [1-4].   
This report is in extension of that presented in IJSBAR by the current researcher in respect of  “site attachment 
inhibition (or, negation of cellular attachment by viruses)” as a new pathway for development of antiviral drugs 
(therapies) given the lack of success by the two pathways established to date which have focused on: virus 
replication; and, immune system enhancement" [4-7].  In that research report, the new antiviral treatment 
pathway was clearly delineated and supported in a number of ways including the example of HIV with CCR5-
Δ32 mutation creating innate resistance (or, immunity) by way of the subsequent site attachment inhibition, in 
addition to blockade and antagonism support [8-9]. 
The current report explores the potential for analogous development in respect of bacterial infection.  That is, 
the conceptualization of site attachment inhibition (or, negation of cellular attachment by bacteria) as a new 
pathway for antimicrobial treatment.  
2. Attachment of Bacteria to Cells 
Bacteria attach to human cells through a bacterial adhesin to form bonds (including covalent bonds) with the 
human cells.  Bacteria sometimes reside on the surface of human cells but can also enter the cells.  At this stage, 
there are two key fundamentals to take from this [10]: 
1. The attachment by bacteria to glycoprotein receptors 
2. The attachment mechanism through adhesins and formation of covalent bonds 
The report will, therefore, continue by way of consideration with respect to the above two key fundamentals as 
the systematic process for pathway development.  
3. Bacterial Attachment: Glycoprotein Receptor Attachment 
Common receptors for attachment by bacteria to human cells are glycoprotein receptors.  This would suggest a 
possible approach to site attachment inhibition (negation of cellular attachment by bacteria) may be represented 
by "glycoprotein receptor antagonism" or "glycoprotein receptor blockade.” In considering the potential support 
for success of this strategy: 
(1)Treatment of specific blood disorders (requiring negation of platelet aggregation and thrombus formation) 
utilize a class of drugs (medications) termed Glycoprotein IIb/IIIa inhibitors [6], and it seems reasonable to 
suggest that inhibition, antagonism, or blockade of other glycoprotein receptors, in addition to any other 
receptors of relevance, would be worth considering seriously as a potential pathway for treatment of bacterial 
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infections.  
(2) The human immune system attempts to coat infective agents (bacteria, viruses and the like) as a means to 
negate attachment by bacteria (and other infective agents) to the human cells [11], and therefore it makes 
scientific sense to pursue this new pathway for antibacterial development.  
Although the scientific support (evidence) for this pathway with respect to bacteria is not as robust as that for 
site attachment inhibition of viruses, presented in the previous report published in IJSBAR, taking into account 
increasing threats posed by resistant bacteria globally, the pathway impresses as worthy of pursuit.  
4. The attachment through adhesins and covalent bonds 
Bacteria commonly form bonds when attaching to human cells through adhesins and covalent bonds, whether 
the category of bacteria is of that which resides on the surface of human cells or of a category that enters human 
cells.  It is therefore worth considering, as a further method for site attachment inhibition (negation of cellular 
attachment by bacteria) the pathway represented by breaking adhesins and covalent bonds.  
The pathway at this stage would be exploratory and would likely (for each type of bacteria) involve the 
exploration of: 
1. Electromagnetic radiation that may break (or, destroy) the given adhesins and covalent bonds 
2. Chemicals that may break (or, destroy) the given adhesins and covalent bonds  
3. Other vibrating waveforms, temperatures, and agents that may break (or, destroy) the given 
adhesins and covalent bonds  
In considering the potential support for success of this strategy there has been a degree of research to 
demonstrate that perhaps radiation can kill infective organisms including bacteria [12,13].   
5. Areas for further research: 
Further research may be directed toward other infective agents including fungi, parasites and other relevant 
agents.  In addition, the mechanisms above (e.g. electromagnetic radiation and other) may be explored in respect 
of their ability to directly kill (destruct) the given infective agents of interest, in addition to the strategic method 
of site attachment inhibition (negation of cellular attachment by bacteria). Other axes of combat with regards to 
negation of cellular attachment by infective agents should be explored.  For instance, gene therapy to target 
disruption of the DNA of the given infective agent (example, bacteria) from forming the apparatus used in 
attachment to the human cells.  At present, gene therapy in combating infectious diseases essentially focuses on 
disrupting the cellular replication of the given infective agent. 
With respect to the previous publication in IJSBAR, and not wanting to depart too far from the topic at hand, it 
may also be worth investigating measures including knockout of genes in the prenatal (or, earlier) stages of 
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development as a means to prevent cancer, for instance the knockout of proto-oncogenes.   
One further area to explore may be with respect to the merger of technology and biology.  The merger of 
technology and biology has become increasingly evident with examples being attempts at three dimensional 
printing of human organs and the use of analogous reasoning as supportive data in process development of new 
strategic antimicrobial pathways.  There are also predicted developments in areas, at a minimum, revolving 
around: downloadable consciousness; and, technological mapping of the human CNS [14,15].  It may be an 
option to explore, given the increasing trend for merging biology and technology, whether infective agents can 
be integrated into advanced computing, or quantum, analytical systems in order to derive solutions, for instance 
a destructive waveform or vibration.  In further support of the above, other literature also espouses biological 
infective agents as similar to information technology infective agents (or, viruses) and it would not seem likely 
that resources would be wasted in exploration of methods to analyze IT equivalents of the given infective agents 
in order to derive a solution able to be converted back to a biologically applicable form [1,16].   
The above being said, it should be stated that advances in such areas as downloadable consciousness and the 
merging of biology with technology raises definite ethical considerations that should be considered by society 
and ethics committees.  The author of the current report has assessed in a previous report the possibility of even 
viruses containing some degree of consciousness (or, at least an ability to sense surroundings) [1].     
Whilst the above may seem some way down the track, the prospect may be nearer than first impressions may 
suggest given the mind mapping goals set by the Brain Initiative program commenced in America [15].   
6. Summary  
The previous report in IJSBAR by the current researcher identified significant issues: A) The lack of successful 
antiviral drugs (therapies) despite many years of pursuit; B) No cure for HIV despite many years of exploration. 
The pathways to combat HIV and other viruses to date: 1) virus replication; 2) enhancement of immune 
function.  Furthermore, given the lack of success achieved by these two pathways, that it would seem reasonable 
to direct focus at development of a new strategic pathway. The research report presented the development of the 
new strategic pathway for antiviral therapies represented by site attachment inhibition (or, negation of cellular 
attachment by viruses). Further to this, HIV was used in case analysis with strategic measures detailed including 
prenatal genetic therapy focusing on mutagenesis and knockout, targeted at genes (receptors; and, surface 
proteins) including CCR5 and CXCR4, as a means of achieving innate resistance (immunity) similar to the 
known CCR5-Δ32 mutation, in addition to treatment strategy following established infection designed to block 
attachment of the virus to CCR5 and CXCR4, including antagonism and blockade of the receptors (analogous to 
beta blockade), stem cell therapy, radiation, and targeted therapy designed to attack the mechanisms of the virus 
in its attachment ability to the given receptors (CCR5, CXCR4) and any other relevant. Support for site 
attachment inhibition strategy was further consolidated through consideration with respect to advanced 
information technology in which one key mechanism for virus removal is represented by negation of site 
attachment.  
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The current report has presented, in extension of the aforementioned research, the development and 
conceptualization of site attachment inhibition of bacteria (or, negation of cellular attachment by bacteria).  At 
this stage, there are two key fundamentals to take from this: 
1. The attachment by bacteria to glycoprotein receptors 
2. The attachment mechanism through adhesins and formation  of covalent bonds 
In considering the potential support for success of this strategy: 
(1) Treatment of specific blood disorders (requiring negation of platelet aggregation and thrombus formation) 
utilize a class of drugs (medications) termed Glycoprotein IIb/IIIa inhibitors [6], and it seems reasonable to 
suggest that inhibition, blockade or antagonism of other glycoprotein receptors would be worth pursuing as a 
potential pathway for treatment of bacterial infections.  
(2) The human immune system attempts to coat infective agents (bacteria, viruses and the like) as a means to 
negate attachment by bacteria (and other infective agents) to the human cells [11], and therefore it makes 
scientific sense to pursue this new pathway for antibacterial development.  
This pathway regarding site attachment inhibition (i.e. for bacteria) may not be as robust at this stage as that for 
viruses presented in the previous report however, given the current global context of antibiotic resistance, would 
definitely seem worth pursuing.    
Based on the evidence, including the innate immunity (resistance) achieved by CCR5-Δ32 mutation, it seems 
optimistic that there is potential for site attachment inhibition to be a successful therapeutic modality by itself in 
respect of viruses without requiring polypharmacy or adjunctive treatments.  It is not entirely clear whether in 
respect of bacteria the likelihood of site attachment inhibition being a successful modality purely by itself is 
perhaps lower due to the enhanced ability of bacteria to survive in conditions of site attachment negation given 
the reduced (or lack of) reliance, relative to viruses, on the internal machinery of human cells.   
7. Conclusion  
This report presents the development and conceptualization of site attachment inhibition of bacteria (or, 
negation of cellular attachment by bacteria) as a new pathway in antimicrobial therapeutics, in addition to 
consideration of other potential pathways. 
The pathway appears viable, although not appearing as robust at this stage as that for antiviral therapy presented 
previously by the current researcher in IJSBAR.  That being said, particularly given the current context of 
antibiotic resistance, it seems reasonable to suggest the pathway as worth pursuing.      
In conclusion, the research presented by the author of the current and previous reports has developed and 
conceptualized the new strategic pathway for combatting infective agents represented by site attachment 
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inhibition (or, negation of cellular attachment by infective agents). This is particularly important in the current 
global context of antibiotic resistance and deficiencies in effective antiviral drugs (therapies).   
The researcher of the current report has been invited to present the new strategic pathway delineated, 
specifically site attachment inhibition (or, negation of cellular attachment by infective agents), at the 6th 
International Conference on Immunology (USA; Chicago IL 870th Congress) and related presentations of the 
official International Conference Series Umbrella including Rome, Italy.    .   
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